Document:

Exhibit 10.1

 

		
        

        Arconic

        201 Isabella Street

        Pittsburgh, PA 15212-5858

         

        John C. Plant

        CEO
 & Chair, Board of Directors 

 

January 13, 2020

 

Timothy Myers

1720 East Haymarket Way

Hudson, OH 44236

  

Dear Tim:

 

As we have discussed, on behalf of Arconic Inc. (the “Company”),
I am pleased to offer you the position of Chief Executive Officer of Arconic Corporation effective upon the legal separation of
Arconic Corporation from Arconic Inc. (such separation, the “Spinoff,” and the date of such separation, “Legal
Day 1”), and, from and after the Spinoff, references herein to the Company shall be deemed to refer to Arconic Corporation,
unless the context clearly indicates otherwise.

 

Prior to Legal Day 1, you will continue in your current role
and you will report directly to me. On and after Legal Day 1, you will report directly to the Board of Directors of Arconic Corporation
(the “Board”). You will also be appointed as a member of the Board, effective as of Legal Day 1. During your employment
with the Company, you will devote substantially all of your working time and attention to the business and affairs of the Company
(excluding any vacation to which you are entitled) and you will comply with the Company’s policies and rules, as in
effect from time to time.

 

Set forth below is your total compensation package, together
with other important information.

 

Base Salary:

 

On Legal Day 1, your annual base salary will become $850,000
paid on a monthly basis in accordance with the Company’s normal payroll practices, and subject to all applicable taxes and
withholdings.

 

Incentive Compensation:

 

You will initially be eligible for a target annual cash incentive
compensation opportunity of 125% of your base salary (i.e., $1062,500 based on your initial base salary) for a full year, if individual
and business performance targets are met. Actual payouts could be higher or lower than target depending on individual and business
performance. Your annual cash incentive compensation opportunity and award for 2020 will be prorated to reflect the portion of
the year that you are CEO of Arconic Corporation (i.e., a blended rate will apply, with your current target annual cash incentive
opportunity applying to the portion of 2020 prior to Legal Day 1, and with the target annual cash incentive opportunity set forth
in this paragraph applying to the remainder of the year).

 

     

     

    

 

Equity Compensation:

 

You will be eligible for annual equity compensation awards in
connection with the Company’s regular annual grant cycles.  For your first such award, to be issued legal day one, you
will be granted (i) a restricted share unit award with a grant date value of $1,720,000, which will vest on the third anniversary
of the grant date, subject to your continued employment with the Company through such date and (ii) a performance-based restricted
share unit award with a grant date value (at target) of $2,580,000, which will be subject to performance goals applicable to Arconic
Corporation, as well as to your continued employment with the Company through the third anniversary of the grant date (together,
the “RSUs”). The RSUs shall be granted under the 2013 Arconic Stock Incentive Plan and shall be subject to Restricted
Share Unit Terms and Conditions consistent with those applicable to 2020 annual awards to Company senior executives generally,
it being understood that it is anticipated that as of the Spinoff the RSUs will be adjusted into awards of Arconic Corporation.

 

For each subsequent calendar year (starting in 2021) in which
you are employed by the Company, you shall be eligible to receive additional grants of equity-based and other long-term incentives
offered to senior executives generally, at a level, and on terms and conditions, that are commensurate with your positions and
responsibilities at the Company, and appropriate in light of your performance and of corresponding awards (if any) to other senior
executives of the Company (in all cases, as determined in good faith by the Board or a committee thereof).

 

Equity Ownership Requirements:

 

Consistent with Arconic Inc.’s efforts to align the interests
of its senior leadership with the interests of Arconic shareholders, Arconic Inc. has adopted equity ownership requirements for
senior Arconic Inc. executives and it is anticipated that Arconic Corporation will adopt similar requirements. You will be subject
to these requirements, currently 6.0 times base salary for the Chief Executive Officer, during your employment with the Company.
Until equity ownership requirements are met, you are required to retain 50% of shares acquired upon vesting of restricted stock
units and performance-based restricted stock units or upon exercise of stock options, after deducting those used to pay for applicable
taxes and/or the exercise price.

 

Relocation:

 

No later than September 30, 2020, you will relocate and establish
a permanent residence in the Pittsburgh, PA metropolitan area. The Company provides a Transfer and Relocation Plan, the terms of
which are determined by the Company in its discretion from time to time, to help facilitate your permanent relocation.

 

Benefits:

 

You will continue to be eligible to participate in Company benefit
plans as in effect from time to time on the terms applicable to Company senior executives generally (subject to the applicable
eligibility and other requirements set forth therein).

 

Confidentiality, Developments, Non-Competition
and Non-Solicitation Agreement:

 

In consideration of your employment with
the Company, you agree to execute the Confidentiality, Developments, Non-Competition and Non-Solicitation Agreement attached hereto
as Annex A.

 

    2 

     

    

 

Severance:

 

On Legal Day 1, you will be designated as a Tier I Employee
under each of the Company’s Executive Severance Plan and Change in Control Severance Plan (together, the “Severance
Plans”) and you will participate at the same level under the corresponding plans anticipated to be adopted by Arconic Corporation
(it being understood that following the Spinoff, references in this letter to the Severance Plans or either Severance Plan shall
be deemed to refer to such corresponding plans of Arconic Corporation). Your participation in such plans is subject to the terms
and conditions of such plans as in effect from time to time. You acknowledge that the Company has informed you that it anticipates
reducing the Tier I Employee multipliers under the Severance Plans by .5 (i.e., the multiplier under Section 2.1(a)(i) of the Company’s
Executive Severance Plan would become 1.5 and the Applicable Period thereunder would become 18 months, and the Applicable Multiplier
and Applicable Period under the Company’s Change in Control Severance Plan would become 2.5 and 30 months, respectively)
and you hereby consent to any amendment effectuating such reductions, without regard to the one-year limitation on effectiveness
of amendments under the Company’s Executive Severance Plan.

 

Indemnification:

 

You will be covered as an insured officer
under the Company’s director and officer liability insurance policy, as in effect from time to time, to the same extent,
and on the same terms, as other executive officers of the Company.

 

Section 409A:

 

The payments and benefits provided under
this letter are intended to comply with, or be exempt from, the requirements of Section 409A of the Internal Revenue Code of 1986,
as amended, and the provisions of this letter shall be interpreted and applied consistently with such intent. All reimbursements
under this letter that constitute deferred compensation within the meaning of Section 409A will be made or provided in accordance
with the requirements of Section 409A, including, without limitation, that (i) in no event will any reimbursement payments be made
later than the end of the calendar year next following the calendar year in which the applicable expenses were incurred; (ii) the
amount of reimbursement payments that the Company is obligated to pay in any given calendar year shall not affect the amount of
reimbursement payments that the Company is obligated to pay in any other calendar year; and (iii) your right to have the Company
pay such reimbursements may not be liquidated or exchanged for any other benefit.

 

Miscellaneous:

 

Your employment with the Company will at
all times be at-will. Subject to your rights to the payments and benefits upon certain termination of employment in accordance
with the terms of the Executive Severance Plan and the Change in Control Severance Plan, in each case, as in effect from time to
time, and this letter, nothing herein will confer upon you any right to continue in the employment of the Company for any period
of specific duration or interfere with or otherwise restrict in any way the rights of the Company or you to terminate your employment
at any time and for any reason, with or without cause. Upon your termination of employment for any reason and as a condition to
any payments and benefits to which you may become entitled under the Company’s Executive Severance Plan, Change in Control
Severance Plan, or this letter, at the request of the Board you will immediately resign from the Board, your position as an officer
of the Company and all offices and directorships of all subsidiaries and affiliates of the Company. Any waiver of any breach of
this letter shall not be construed to be a continuing waiver or consent to any subsequent breach on the part of either you or the
Company. All payments hereunder shall be subject to applicable tax withholding.

 

    3 

     

    

 

Successors:

 

This Agreement shall be assigned to Arconic
Corporation, effective Legal Day 1. Other than Arconic Inc.’s assignment of this Agreement to Arconic Corporation on Legal
Day 1, neither party hereto may assign any rights or delegate any duties under this letter without the prior written consent of
the other party; provided, however, that this letter shall inure to the benefit of and be binding upon the successors and assigns
of the Company upon any sale of all or substantially all of the Company’s assets, or upon any merger, consolidation or reorganization
of the Company with or into any other corporation, all as though such successors and assigns of the Company and their respective
successors and assigns were the Company.

 

Entire Agreement:

 

Except as otherwise contemplated herein,
this letter contains the entire agreement between you and the Company with respect to the subject matter hereof. No modification
or termination of this letter may be made orally, but must be made in writing and signed by you and the Company.

 

In the event that the Spinoff has not been
consummated as of July 31, 2020 (as such date may be extended by mutual agreement of you and the Company), this letter agreement
shall be null and void ab initio.

 

Governing Law; Jurisdiction:

 

This letter will be governed and interpreted
in accordance with the laws of the State of Delaware without reference to its choice of law principles. Any action arising out
of or related to this letter will be brought in the state or federal courts with jurisdiction in Delaware, and you and the Company
consent to the jurisdiction and venue of such courts.

 

[Signature page follows.]

 

    4 

     

    

 

To accept our offer, please sign and date the bottom of this
letter and return it to me by January 14, 2020. If you have any questions, please feel free to call me.

 

I look forward to your contributions to the future of Arconic
Corp.

 

Best Regards,

 

/s/ John C. Plant

 

John C. Plant

CEO and Chair, Arconic Inc. Board of Directors

  

cc:       Neil Marchuk 

 

Attachments: 

Confidentiality, Developments, Non-Competition and Non-Solicitation
Agreement

  

 

 

I, Timothy Myers, am pleased to accept your offer of employment
dated January 13, 2020, for the position of Chief Executive Officer Arconic Corp. in the terms detailed in the offer letter.

  

	Accepted by:	 	Date:	 
	 	 	 	 
	 	 	 	 
	/s/ Timothy Myers	 	January 13, 2020	 

Timothy Myers

 

[Signature Page]

 

     

     

    

 

Exhibit A

 

Confidentiality, Developments, Non-Competition,
and Non-Solicitation Agreement

 

As an employee of Arconic
Inc. (“Arconic”) or one of its subsidiaries (Arconic collectively with its subsidiaries, the “Company”),
you (“you” or “Employee”) will have access to or may develop confidential and proprietary information (as
defined below) of the Company. Therefore, in consideration of your employment, and recognizing the highly competitive nature of
the Company’s business, you enter into this Confidentiality, Non-Competition, and Non-Solicitation Agreement (this “Agreement”)
intending to be legally bound.

 

Confidentiality

 

You acknowledge that,
as an employee of the Company, you have access, and are privy, to information which is confidential and proprietary to the Company
and which is not generally available to the public from sources outside of the Company.

 

You agree to regard
and preserve as confidential any and all Confidential Information pertaining to the Company’s operations and affairs and
all information which is either learned or obtained by you during your employment, and which you know, or have reason to believe,
includes Confidential Information. You agree that you will use Confidential Information only for the performance of your duties
for the Company and you agree not to disclose any Confidential Information you acquire, except as expressly permitted below. You
understand and agree that this obligation of confidentiality shall continue indefinitely following the termination of your employment
with the Company.

 

Nothing in this Agreement
shall prohibit or restrict you from: (i) making any disclosure of relevant and necessary information or documents in any action,
investigation, or proceeding relating to this Agreement, or as required by law or legal process; or (ii) participating, cooperating,
or testifying in any action, investigation, or proceeding with, or reporting possible violations or providing information to, any
governmental agency or legislative body regarding this Agreement or the Company, including, but not limited to, the Company’s
Legal Department, the Securities & Exchange Commission, and/or pursuant to the Dodd-Frank Act (including without limitations
the whistleblower provisions thereof) or Sarbanes-Oxley Act; provided that, other than with respect to providing information to
a governmental agency and to the extent permitted by law, upon receipt of any subpoena, court order or other legal process compelling
the disclosure of any such information or documents, you will give the General Counsel of the Company prompt written notice so
as to permit the Company to protect its interests in confidentiality to the fullest extent possible. Notwithstanding any provision
of this Agreement to the contrary, the provisions of this Agreement are not intended to, and shall be interpreted in a manner that
does not, limit or restrict you from exercising any legally protected whistleblower rights (including pursuant to Rule 21F under
the Securities Exchange Act of 1934, as amended).

 

Upon termination of
your employment or at any time requested by the Company, you will deliver promptly to the Company all memoranda, notes, records,
reports and other documents (whether in paper or electronic form and all copies thereof) relating to the business of the Company
and all other Company property which you obtained or developed while employed by, or otherwise serving or acting on behalf of,
the Company and which you may then possess or have under your control, whether directly or indirectly.

 

    	 	 A-1	 

     

    

 

Disclosure of Developments and Other
Inventions

 

Without disclosing
any third party confidential information, Employee shall promptly disclose to Company all Developments and any inventions or developments
that Employee believes do not constitute a Development, so that Company can make an independent assessment. Employee represents
and warrants that if Employee developed, conceived or created any Development or other Intellectual Property prior to the date
hereof that relates to Company’s Business, Employee has listed such Intellectual Property on Appendix 1 in a manner that
does not violate any third party rights or disclose any third party confidential information.

 

Ownership of Developments

 

Ownership: All
right, title and interest (including all Intellectual Property rights of any sort throughout the world) relating to any and all
Developments (other than Employee Statutorily Exempt Developments) shall be the exclusive property of Company.

 

Assignment of Rights:
In consideration of Employee’s employment by Company as set forth in the Employment Agreement, Employee hereby assigns to
Company or its designee any and all right, title and/or interest (including all Intellectual Property rights of any sort throughout
the world) in and to any Developments that Employee has or may in the future acquire with respect to any Developments, provided
that this section shall not apply to any Employee Statutorily Exempt Developments.

 

Further Assistance
and Assurances: Employee shall, both during and after his/her employment by Company, at the expense of Company, perform all
lawful acts requested by, or on behalf of, Company to enable Company to obtain, perfect, sustain, and enforce its ownership interest
in any Development(s) in accordance with this Section and to obtain and maintain patents, copyrights and other Intellectual Property
rights for such Development(s) throughout the world.

 

Attorney-In-Fact:
Employee hereby irrevocably designates and appoints Company as Employee’s agent and attorney-in-fact, coupled with an interest
and with full power of substitution, to act for and on Employee’s behalf to execute and file any document and to do all other
lawfully permitted acts to further the purposes of this Section with the same legal force and effect as if executed by Employee.

 

Acknowledgement
of Employee Statutorily Exempt Developments: Employee acknowledges and agrees that, by executing this Agreement, nothing in
this Agreement is intended to expand the scope of protection provided to Employee by Sections 2870 through 2872 of the California
Labor Code or any other statute of like effect. Employee agrees to promptly advise the Company in writing of any developments that
Employee believes may qualify under Sections 2870 through 2872 of the California Labor Code or any other statute of like effect.

 

Records: Employee
agrees to keep and maintain adequate and current records (in the form of notes, sketches, drawings, and in any other form that
may be required by the Company) of all Developments made, written, conceived and/or reduced to practice by Employee during the
period of employment by Company, which records shall be available to and remain the sole property of the Company at all times.

 

Employee IP –
Ownership and Restrictions; License: Any discovery, invention, improvement, computer program and related documentation or other
work that (i) is created during the term of Employee’s employment with the Company and does not fall within the definition
of the term “Development” as defined herein, (ii) is an Employee Statutorily Exempt Development, or (iii) was developed,
created, or conceived prior to Employee’s employment with Company shall, as between Company and Employee, belong to Employee
and shall not be used by Employee in his or her performance on behalf of the Company. Without limiting Company’s other rights
and remedies, if, when acting within the scope of Employee’s employment or otherwise on behalf of Company, Employee uses
or discloses Employee’s own or any third party’s confidential information or other Intellectual Property in violation
of this Agreement (or if any Development cannot be fully made, used, reproduced, distributed and otherwise exploited without using
or violating the foregoing), Employee hereby: (a) grants to Company a perpetual, irrevocable, worldwide, fully-paid, royalty-free,
non-exclusive, sub-licensable right and license to use, exploit and exercise all such confidential information and/or Intellectual
Property rights; and (b) warrants that he/she is entitled to grant such license to the extent the confidential information or Intellectual
Property used by Employee in violation of this Section belongs to a third party.

 

    	 	 A-2	 

     

    

 

Restrictive Covenants

 

Non-Competition:
During your employment and for a period of one year thereafter (regardless of whether the termination of your employment is voluntary
or involuntary), you will not directly or indirectly (i) engage in, carry on, or provide services (paid or unpaid) whether as a
director, officer, partner, owner, employee, inventor, consultant, advisor, or agent, to any Competitive Business (as defined below)
or (ii) hold any economic interest in any Competitive Business. However, notwithstanding the foregoing, you may own up to five
percent (5%) of the outstanding securities of any publicly traded company and you shall not be prohibited from becoming employed
by, or associated with, a private equity firm or hedge fund (or one of their portfolio companies) that has an investment in a Competitive
Business as long as you have no involvement whatsoever with such Competitive Business (including the formation, planning, or acquisition
of, or investment in, any such Competitive Business).

 

It is not the Company’s
intention to restrict or limit your activities following your termination of employment with the Company unless it is believed
that there is a substantial possibility that your future services or activities in any of the lines of business in which the Company
is engaged may be detrimental to the Company. So as to not unduly restrict your future employment, if you desire to enter into
any employment arrangement or relationship with any potential Competitive Business within the one-year restricted period, please
consult with the Executive Vice President of Human Resources of Arconic/Howmet to discuss your intended relationship with the entity.
Due to the many different businesses in which the Company presently engages, or which in the future the Company may engage, we
will discuss your desire to enter into a business or professional relationship with any manufacturer or firm which is a Competitive
Business. The Company’s consent will not be unreasonably withheld.

 

Also, as a reminder,
Arconic/Howmet stock incentive awards continue to be subject to forfeiture, under the terms of that program, to the extent you
become associated with, employed by, render services to, or own any interest in any business that is in competition with the Company
or if you engage in willful conduct that is injurious to the Company.

 

Non-Solicitation:
During your employment and for a period of one year thereafter (regardless of whether the termination of your employment was voluntary
or involuntary), you will not directly or indirectly (i) solicit, induce or attempt to solicit or induce any employee of the Company
to leave the Company for any reason; (ii) hire or attempt to hire any employee of the Company; or (iii) solicit business from,
or engage in business with, any customer or supplier of the Company that you met and/or dealt with during your employment with
the Company for any purpose. In the event that you become aware that any employee of the Company has been hired by any business
or firm with which you are then affiliated, you will immediately notify the Executive Vice President of Human Resources of Arconic/Howmet
to confirm your non-solicitation of said employee

 

    	 	 A-3	 

     

    

 

You acknowledge and
agree that given the nature of the Company’s business, which is conducted throughout the world, the unique and extraordinary
services you will be providing to the Company and your position of confidence and trust with the Company, the scope and duration
of the covenants included in this Agreement (the “Restrictive Covenants”) are reasonable and necessary to protect the
legitimate business interests of the Company. You further acknowledge that you have received substantial consideration from the
Company and that your general skills and abilities are such that you can be gainfully employed in noncompetitive employment, and
that this Agreement will in no way prevent you from earning a living following your employment with the Company.

 

You also recognize
and agree that any breach or threatened or anticipated breach of any part of these Restrictive Covenants will result in irreparable
harm to the Company, and that the remedy at law for any such breach or threatened breach will be inadequate. Accordingly, in addition
to any other legal or equitable remedies that may be available to the Company, you agree that the Company will be entitled to obtain
an injunction, without posting a bond, to prevent any breach or threatened breach of any part of these Restrictive Covenants.

 

In the event that any
court of competent jurisdiction finds that the limitations set forth in these Restrictive Covenants are overly broad with respect
to duration, geographic scope or scope of prohibited activities, such court will have the authority to reduce the duration, area
or activities of such provisions so as to be enforceable to the maximum extent compatible with applicable law, and such provisions
will then be enforced as modified.

 

Notice of Immunity – Defend
Trade Secrets Act of 2016

 

Company employees,
contractors, and consultants may disclose Trade Secrets in confidence, either directly or indirectly, to a Federal, State, or local
government official, or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law, or in
a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Additionally, Company
employees, contractors, and consultants who file retaliation lawsuits for reporting a suspected violation of law may disclose related
Trade Secrets to their attorney and use them in related court proceedings, as long as the individual files documents containing
the Trade Secret under seal and does not otherwise disclose the Trade Secret except pursuant to court order.

 

Definitions
for Purposes of this Agreement

 

“Business”
means areas of actual or demonstrably anticipated research and development conducted (or to be conducted) by, or for the benefit
of, Company as well as all products or services sold by, on behalf of, or for the benefit of Company worldwide.

 

“Competitive
Business” means any domestic or international business or firm (including any business in the process of being formed or
planned) that is engaged, or has active plans to become engaged, in any line of business of the Company with which you have had
direct functional accountability, or for which you provided leadership or support, during your last eighteen (18) months of employment
with the Company.

 

“Confidential
Information” includes, but is not limited to strategic plans, trade secrets, inventions, discoveries, technical and operating
know-how, accounting information, product information, marketing and sales data, business strategies, customer information, and
employee data of the Company that is proprietary in nature, and any similar information, data or materials of third parties that
the Company has a duty to keep confidential

 

    	 	 A-4	 

     

    

 

“Developments”
means all discoveries, inventions, innovations, improvements, computer programs and related documentation, and other works of authorship,
mask works, designs, know-how, ideas and information made, written, conceived and/or reduced to practice, in whole or in part,
(whether or not patentable or subject to other forms of protection) by Employee, individually or with any other person, during
and after the period of Employee’s employment by Company that: (a) relate in any manner to the Business or activities of
Company; and/or (b) are created: (i) at any time using Company resources, including, but not limited to, Company computers, cellphones,
smartphones, etc.; (ii) during working hours; (iii) at a Company facility; (iv) by, or on behalf of, Company; and/or (v) using
Confidential Information.

 

“Employee Statutorily
Exempt Developments” means any Developments which qualify fully under the provisions of any applicable statute (including,
e.g., Section 2870 of the California Labor Code) that prohibits the assignment to Company of Employee’s rights in any inventions
developed entirely on Employee’s own time without using the Company’s equipment, supplies, facilities, resources, trade
secrets or Confidential Information (i.e., excluding inventions that either (i) relate at the time of conception or reduction to
practice of the invention to the Company’s Business, or actual or demonstrably anticipated research or development; or (ii)
result from any work performed by Employee for the Company).

 

“Intellectual
Property” means any intellectual and industrial property and all rights thereof, including, but not limited to, patents,
utility models, semi-conductor topography rights; copyrights, mask works, authors’ rights, registered and unregistered trademarks,
brands, domain names, trade secrets, know-how and other rights in information, drawings, logos, plans, database rights, technical
notes, prototypes, processes, methods, algorithms, any technical-related documentation, any software, registered designs and other
designs, in each case, whether registered or unregistered and including applications for registration, and all rights or forms
of protection having equivalent or similar effect anywhere in the world.

 

Governing Law; Jurisdiction

 

This Agreement will
be governed and interpreted in accordance with the laws of the State of Delaware without reference to its choice of law principles.
Any action arising out of or related to this Agreement will be brought in the state or Federal courts located in Delaware, and
you and the Company consent to the jurisdiction and venue of such courts.

 

Amendment; Waiver

 

No provision of this
Agreement may be modified, waived, or discharged unless such waiver, modification or discharge is in writing. Any failure by you
or the Company to enforce any of the provisions of this Agreement should not be construed to be a waiver of such provisions or
any right to enforce each and every provision in the future. A waiver of any breach of this Agreement will not be construed as
a waiver of any other or subsequent breach.

 

Successors; Binding Agreement

 

Upon the legal separation
of Arconic Corporation from Arconic Inc. (such separation, the “Spinoff”), this Agreement will be assigned to Arconic
Corporation and, from and after the Spinoff, all references herein to “Arconic” shall be deemed to refer to Arconic
Corporation and all references herein to the “Company” shall be deemed to refer to Arconic Corporation collectively
with its subsidiaries, unless the context clearly indicates otherwise.

 

    	 	 A-5	 

     

    

 

The Company has the
right to assign its rights and obligations under this Agreement to any entity that acquires all or substantially all of the assets
of the business for which you work, and continues your employment. The rights and obligations of the Company under this Agreement
will inure to the benefit and be binding upon the successors and assigns of the Company

 

Severability

 

In the event that any
one or more of the provisions of this Agreement is held to be invalid, illegal or unenforceable, the validity, legality and enforceability
of the remainder of this Agreement will not in any way be affected or impaired thereby.

 

This Agreement is the
entire agreement between the parties with respect to the matters covered by this Agreement and it replaces all previous agreements,
oral or written, between the parties regarding such matters. PROVISIONS OF THIS AGREEMENT MAY NOT BE WAIVED OR CHANGED EXCEPT BY
A SUBSEQUENT AGREEMENT SIGNED BY YOU AND AN OFFICER OF THE COMPANY.

 

If you agree to the
terms of this Agreement, please sign on the line provided below and return two signed copies. A fully executed copy will be returned
to you for your files after it is signed by the Company.

 

ARCONIC INC.

 

	By: 	/s/ Neil Marchuk	 
	 	 	 
	AGREED
    TO AND ACCEPTED AS OF THIS 13TH DAY OF JANUARY, 2020:
	 	 	 
	 	 	 
	/s/ Timothy
    Myers	 
	Timothy Myers	 

 

    	 	 A-6	 

     

    

 

Appendix 1

 

Prior Employee Inventions 

 

 

 

 

 

    	 	 A-7Exhibit
4.14

 

COMMON
STOCK PURCHASE WARRANT

 

SINTX
TECHNOLOGIES, INC.

 

	Warrant
    Shares: [_______	Initial
    Exercise Date: [____, 2020

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns
(the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m.
(New York City time) on [_____]1 (the “Termination Date”) but not thereafter, to subscribe for and
purchase from SINTX Technologies, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject
to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock
under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and
maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”)
shall initially be the sole registered holder of this Warrant, subject to a Holder’s right to elect to receive a Warrant
in certificated form pursuant to the terms of the Warrant Agency Agreement, in which case this sentence shall not apply.

 

Section
1. Definitions. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section 1:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Bid
Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common
Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX
as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common
Stock are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency
succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith
by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and
expenses of which shall be paid by the Company.

 

 

1
Insert the date that is the five year anniversary of the effective date of the registration statement.

 

    	 	1	 

     

    

 

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Common
Stock” means the common stock of the Company, par value $0.01 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.

 

“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Registration
Statement” means the Company’s registration statement on Form S-1 (File No. 333-234438) and any prospectus included
therein in compliance with Rule 424(b) of the Securities Act.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Subsidiary”
means any subsidiary of the Company an shall, where applicable, also include any direct or indirect subsidiary of the Company
formed or acquired after the date hereof.

 

“Trading
Day” means a day on which the Common Stock is traded on a Trading Market.

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market
or the New York Stock Exchange (or any successors to any of the foregoing.

 

“Transfer
Agent” means American Stock Transfer & Trust Company, LLC, the current transfer agent of the Corporation with a
mailing address of [  ] and a facsimile number of [  ], and any successor transfer agent of the Company.

 

    	 	2	 

     

    

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX
as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common
Stock are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency
succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith
by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and
expenses of which shall be paid by the Company.

 

“Warrant
Agency Agreement” means that certain warrant agency agreement, dated on or about the Initial Exercise Date, between
the Company and the Warrant Agent.

 

“Warrant
Agent” means the Transfer Agent and any successor warrant agent of the Company.

 

“Warrants”
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.

 

Section
2. Exercise.

 

a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly
executed facsimile copy or PDF copy submitted by email (or e-mail attachment) of the Notice of Exercise in the form annexed hereto
(the “Notice of Exercise”). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days
comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid,
the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer
or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below
is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein
to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased
all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender
this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is
delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant
Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in
an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of
Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant,
acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount
stated on the face hereof.

 

    	 	3	 

     

    

 

Notwithstanding
the foregoing in this Section 2(a), a holder whose interest in this Warrant is a beneficial interest in certificate(s) representing
this Warrant held in book-entry form through DTC (or another established clearing corporation performing similar functions), shall
effect exercises made pursuant to this Section 2(a) by delivering to DTC (or such other clearing corporation, as applicable) the
appropriate instruction form for exercise, complying with the procedures to effect exercise that are required by DTC (or such
other clearing corporation, as applicable), subject to a Holder’s right to elect to receive a Warrant in certificated form
pursuant to the terms of the Warrant Agency Agreement, in which case this sentence shall not apply.

 

b)
Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $[_____, subject to adjustment
hereunder (the “Exercise Price”).

 

c)
Cashless Exercise.

 

	   	 i. 	 After the
                                    earlier of (a)       , 20202 or (b) such Trading
                                    Day that the aggregate volume of shares of Common Stock sold since the expiration of the Offering
                                    exceeds three times the number of Common Stock Equivalents sold in the Offering, Holder shall
                                    be permitted to exercise this Warrant, on a cashless basis, regardless of the then applicable
                                    trading price of the Common Stock on the Trading Market, for an aggregate number of Warrant
                                    Shares equal to the product of (i) the aggregate number of Warrant Shares that would be issuable
                                    upon exercise of the Warrants if such exercise were by means of a cash exercise and (ii) 0.70. 

	 	 	 
	 	 ii. 	 Additionally,
    if  at the time of exercise hereof there is no effective
    registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares
    to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise”
    in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B)
    (X)] by (A), where:

 

	 	(A)	=
    	as
    applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice
    of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both
    executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours”
    (as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)
    at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice
    of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the
    time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular
    trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after
    the close of “regular trading hours” on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the
    date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise
    is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such
    Trading Day;

 

 

 2
Insert date that is 30 days after initial exercise date. 

 

    	 	4	 

     

    

 

	 	(B)
    	=	 the
    Exercise Price of this Warrant, as adjusted hereunder; and
	 	 	 	 
	 	(X)
    	=
    	the
    number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
    if such exercise were by means of a cash exercise rather than a cashless exercise.

 

	 	 iii. 	If Warrant Shares
    are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities
    Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
    to take any position contrary to this Section 2(c).
	 	   	 
	 	 iv. 	Notwithstanding anything herein to
    the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this
    Section 2(c).

 

d)
Mechanics of Exercise.

 

	 	i.	Delivery
    of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the
    Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The
    Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company
    is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of
    the Warrant Shares to or resale of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise,
    and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder
    or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address
    specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery
    to the Company by the Holder of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise
    Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to
    the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery of
    the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant
    Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
    provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the
    earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following
    delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject
    to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages
    and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on
    the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading
    Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such
    Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant
    in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement
    Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary
    Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.

  

    	 	5	 

     

    

 

ii.
Delivery of New Warrants Upon Exercise. If this Warrant is not held in global form through DTC (or any successor depositary)
and if this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this
Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights
of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.

 

iii.
Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv.
Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with
the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such
date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage
firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which
the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to
the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that
the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell
order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion
of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall
be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company
timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having
a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate
sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company
shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall
limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

    	 	6	 

     

    

 

v.
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.

 

vi.
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid
by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed
by the Holder; provided, however, that in the event that Warrant Shares are to be issued in a name other than the
name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly
executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for
any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice
of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions)
required for same-day electronic delivery of the Warrant Shares.

 

    	 	7	 

     

    

 

vii.
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

e)
Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not
have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect
to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons,
“Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).
For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates
and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect
to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon
(i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the
Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged
by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of
the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be
the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the
Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d)
of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected
in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent
public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the
number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two Trading
Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number
of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% (or,
upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder,
upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided
that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions
of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until
the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and
implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or
any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained
or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.

 

    	 	8	 

     

    

 

f)
Right of Redemption. Subject to the provisions of Section 2(e) and this Section 2(f), if, at any time at least one (1)
year after the Initial Exercise Date, (i) the VWAP for each of 10 consecutive Trading Days (the “Measurement Period”),
which 10 consecutive Trading Day period shall not have commenced until one (1) year after the Initial Exercise Date) exceeds $[____
(subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and the like after the Initial
Exercise Date) and (ii) the Holder is not in possession of any information that constitutes, or might constitute, material non-public
information which was provided by the Company, any of its Subsidiaries, or any of their officers, directors, employees, agents
or Affiliates, then the Company may, at its sole option and in its sole discretion, redeem not less than all of the outstanding
Warrants for which a Notice of Exercise has not yet been delivered (such right, a “Redemption Right”) for consideration
equal to $[___ per Warrant (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and
the like after the Initial Exercise Date, the “Redemption Price”). For the avoidance of any doubt, to the extent
that the Company determines to exercise its Redemption Right pursuant to this Section 2(f), the Company shall be required to exercise
its Redemption Right with respect to all of the other Warrants issued by the Company pursuant to the Registration Statement. To
exercise the Redemption Right, the Company must deliver to all of the Holders an irrevocable written notice (a “Redemption
Notice”) indicating therein the Company’s election to redeem all of the Warrants and setting forth a date for
the redemption of such Warrants, which date shall be at least thirty (30) days after the date of the Redemption Notice (the “Redemption
Date”). The Redemption Notice shall be mailed by first class mail, postage prepaid, by the Company to the Holders of
the Warrants at their last addresses as they shall appear on the Warrant Register. Any Redemption Notice mailed in the manner
herein provided shall be conclusively presumed to have been duly given on the date sent whether or not the Holder received such
notice. The Warrants may be exercised in accordance with the terms herein at any time after the Redemption Notice shall have been
given by the Company pursuant to this Section 2(f) hereof and prior to the Redemption Date. In furtherance thereof, the Company
covenants and agrees that it will honor all Notices of Exercise with respect to Warrant Shares subject to a Redemption Notice
that are tendered through 6:30 p.m. (New York City time) on the Redemption Date. Following the Redemption Date, the Holders of
the Warrants shall have no further rights except to receive the Redemption Price upon surrender of the Warrants. Notwithstanding
anything to the contrary set forth in this Warrant, the Company may not deliver a Redemption Notice or require the redemption
of this Warrant (and any such Redemption Notice shall be void), unless, from the beginning of the Measurement Period through the
Redemption Date, (1) the Company shall have honored in accordance with the terms of this Warrant all Notices of Exercise delivered
by 6:30 p.m. (New York City time) on the Redemption Date, (2) a registration statement shall be effective as to all Warrant Shares
and the prospectus and all relevant amendments and supplements thereunder available for use by the Company for the sale of all
such Warrant Shares to the Holder, (3) the Common Stock shall be listed or quoted for trading on the Trading Market, (4) there
is a sufficient number of authorized shares of Common Stock for issuance of all Warrant Shares, and (5) the issuance of all Warrant
Shares subject to a Redemption Notice shall not cause a breach of any provision of Section 2(e) herein.

 

Section
3. Certain Adjustments.

 

a)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a)
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

b)
Intentionally omitted.

 

    	 	9	 

     

    

 

c)
Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company
grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata
to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will
be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could
have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result
in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

d)
Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend
or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of
capital or otherwise (including, without limitation, any distribution of stock or other securities, property or options by way
of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution (provided, however, that to the extent that the Holder’s right to participate in any
such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled
to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of
such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder
until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).
To the extent that this Warrant has not been partially or completely exercised at the time of such Distribution, such portion
of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.

 

    	 	10	 

     

    

 

e)
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person (other than a
transaction solely to change the domicile of the Company), (ii) the Company, directly or indirectly, effects any sale, lease,
license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of
related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or
another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares
for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv)
the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged
for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates
a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires
more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or
other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase
agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise
of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation
in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation
or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant
is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise
of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to
apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in
a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder
shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any
Successor Entity (as defined below) shall, at the Holder’s option, exercisable at any time concurrently with, or within
30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable
Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes
Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental
Transaction; provided, however, that, if the Fundamental Transaction is not within the Company’s control,
including not approved by the Company’s Board of Directors, Holder shall only be entitled to receive from the Company or
any Successor Entity, as of the date of consummation of such Fundamental Transaction, the same type or form of consideration (and
in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid
to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in
the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from
among alternative forms of consideration in connection with the Fundamental Transaction. “Black Scholes Value”
means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the “OV” function on
Bloomberg, L.P. (“Bloomberg”) determined as of the day of consummation of the applicable Fundamental Transaction
for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to
the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an
expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined
utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable
Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the
price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental
Transaction and (ii) the greater of (x) the last VWAP immediately prior to the public announcement of such Fundamental Transaction
and (y) the last VWAP immediately prior to the consummation of such Fundamental Transaction and (D) a remaining option time equal
to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date and
(E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds
within five Business Days of the Holder’s election (or, if later, on the effective date of the Fundamental Transaction).
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor
Entity”) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions
of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by
the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver
to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such
Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an
exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such
number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance
to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted
for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company”
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the
obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.

 

    	 	11	 

     

    

 

f)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as
of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

g)
Notice to Holder.

 

i.
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the
Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment
and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ii.
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall
be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a
party (other than a transaction solely to change the domicile of the Company), any sale or transfer of all or substantially all
of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash
or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile
number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable
record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose
of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders
of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become
effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange
their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation,
merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery
thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any
notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the
Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.
The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective
date of the event triggering such notice except as may otherwise be expressly set forth herein.

 

    	 	12	 

     

    

 

Section
4. Transfer of Warrant.

 

a)
Transferability. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with
a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney
and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required,
such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant
evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading
Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if
properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a
new Warrant issued.

 

b)
New Warrants. If this Warrant is not held in global form through DTC (or any successor depositary), this Warrant may be
divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written
notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney.
Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company
shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall
be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

    	 	13	 

     

    

 

c)
Warrant Register. The Warrant Agent shall register this Warrant, upon records to be maintained by the Warrant Agent for
that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company
and the Warrant Agent may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of
any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

Section
5. Miscellaneous.

 

a)
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other
rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth
in Section 3.

 

b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next
succeeding Business Day.

 

d)
Authorized Shares.

 

The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common
Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights
under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers
who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.
The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided
herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common
Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights
represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant
Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens
and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).

 

    	 	14	 

     

    

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform
its obligations under this Warrant.

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.

 

e)
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal
courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either
party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action,
suit or proceeding shall be reimbursed by the other party for their reasonable attorneys’ fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.

 

    	 	15	 

     

    

 

f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities
laws.

 

g)
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting
any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to
cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies
hereunder.

 

h)
Notices. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally
recognized overnight courier service, addressed to the Company, at 1885 West 2100 South, Salt Lake City, Utah 84119, , Attention:
Chief Executive Officer, facsimile number: 855.839.3500, email address: sbal@sintx.com, or such other facsimile number, email
address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications
or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by facsimile or e-mail, or
sent by a nationally recognized overnight courier service addressed to each Holder at the facsimile number, e-mail address or
address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall
be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via
facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City
time) on any date, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via
facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section on a day that is not a Trading
Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice
is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information
regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K.

 

    	 	16	 

     

    

 

i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability
of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted
by the Company or by creditors of the Company.

 

j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not
be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k)
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant
and shall be enforceable by the Holder or holder of Warrant Shares.

 

l)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company,
on the one hand, and the Holder or the beneficial owner of this Warrant, on the other hand.

 

m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.

 

o)
Warrant Agency Agreement. If this Warrant is held in global form through DTC (or any successor depositary), this Warrant
is issued subject to the Warrant Agency Agreement. To the extent any provision of this Warrant conflicts with the express provisions
of the Warrant Agency Agreement, the provisions of this Warrant shall govern and be controlling.

 

********************

 

(Signature
Page Follows)

 

    	 	17	 

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.

 

	 	SINTX
    TECHNOLOGIES, INC.
	 	 	 
	 	By:
    	                              
	 	Name:	 
	 	Title:	 

 

    	 	18	 

     

    

 

NOTICE
OF EXERCISE

 

To:
SINTX TECHNOLOGIES, INC.

 

(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.

 

(2)
Payment shall take the form of (check applicable box):

 

[  ]
in lawful money of the United States; or

 

[  ]
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise
procedure set forth in subsection 2(c).

 

(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity: ___________________________________________________________________________

Signature
of Authorized Signatory of Investing Entity: _____________________________________________________

Name
of Authorized Signatory: _______________________________________________________________________

Title
of Authorized Signatory: ________________________________________________________________________

Date:
___________________________________________________________________________________________

 

    	 	 	 

     

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	 
	 	(Please
    Print)
	 	 
	Address:	 
	 	(Please
    Print)
	 	 
	Phone
    Number:	 
	 	 
	Email
    Address:	 
	 	 
	Dated:
    _______________ __, ______	 
	Holder’s
    Signature: ______________________	 
	Holder’s
    Address: _______________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]